HDAC inhibitors like panobinostat, as a part of multidrug combinations, may reform the current multiple myeloma treatment landscape allowing patients to achieve improved quality of response and prolonged survival, with affordable toxicity. The gene discussed is HDAC9; the disease is AL amyloidosis.